Compare Panacea Biotech with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ASTRAZENECA PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH ASTRAZENECA PHARMA PANACEA BIOTECH/
ASTRAZENECA PHARMA
 
P/E (TTM) x 12.2 73.6 16.6% View Chart
P/BV x 2.9 20.7 14.2% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
ASTRAZENECA PHARMA
Mar-18
PANACEA BIOTECH/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3641,278 28.5%   
Low Rs129883 14.6%   
Sales per share (Unadj.) Rs96.8228.4 42.4%  
Earnings per share (Unadj.) Rs-12.410.4 -119.7%  
Cash flow per share (Unadj.) Rs-2.916.3 -17.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs50.498.8 51.0%  
Shares outstanding (eoy) m61.2525.00 245.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.54.7 53.9%   
Avg P/E ratio x-19.9104.2 -19.1%  
P/CF ratio (eoy) x-86.466.4 -130.1%  
Price / Book Value ratio x4.910.9 44.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m15,10127,008 55.9%   
No. of employees `0002.51.4 182.0%   
Total wages/salary Rs m1,5161,535 98.7%   
Avg. sales/employee Rs Th2,401.94,210.9 57.0%   
Avg. wages/employee Rs Th614.21,132.2 54.2%   
Avg. net profit/employee Rs Th-307.9191.1 -161.2%   
INCOME DATA
Net Sales Rs m5,9285,710 103.8%  
Other income Rs m82123 67.2%   
Total revenues Rs m6,0105,833 103.0%   
Gross profit Rs m845463 182.6%  
Depreciation Rs m585147 397.1%   
Interest Rs m1,0060-   
Profit before tax Rs m-664438 -151.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m99179 55.1%   
Profit after tax Rs m-760259 -293.3%  
Gross profit margin %14.38.1 175.9%  
Effective tax rate %-14.940.8 -36.4%   
Net profit margin %-12.84.5 -282.5%  
BALANCE SHEET DATA
Current assets Rs m5,6033,209 174.6%   
Current liabilities Rs m6,9102,070 333.9%   
Net working cap to sales %-22.020.0 -110.4%  
Current ratio x0.81.6 52.3%  
Inventory Days Days20672 284.5%  
Debtors Days Days8435 239.8%  
Net fixed assets Rs m9,941790 1,257.8%   
Share capital Rs m6150 122.6%   
"Free" reserves Rs m3,0262,419 125.1%   
Net worth Rs m3,0872,469 125.0%   
Long term debt Rs m5,7070-   
Total assets Rs m16,0764,605 349.1%  
Interest coverage x0.3NM-  
Debt to equity ratio x1.80-  
Sales to assets ratio x0.41.2 29.7%   
Return on assets %1.55.6 27.2%  
Return on equity %-24.610.5 -234.6%  
Return on capital %3.917.7 22.1%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,600300 534.1%   
Fx outflow Rs m1,1312,015 56.2%   
Net fx Rs m469-1,715 -27.3%   
CASH FLOW
From Operations Rs m1,18088 1,342.7%  
From Investments Rs m553-94 -590.7%  
From Financial Activity Rs m-1,644NA-  
Net Cashflow Rs m90-6 -1,573.7%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 15.7 8.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 12,856 79.8%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ORCHID PHARMA LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 20, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS